SURGE for Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Dana Farber Cancer Institute, Boston, MA
Lymphoma+3 More
SURGE - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The SURGE(Supporting UnderRepresented minorities in Genomics-based cancer trial Enrollment) intervention is a patient navigation intervention that will support patients in their decision to consent to PROFILE OncoPanel (DFCI protocol 17-000). Consent to PROFILE allows patients to receive genomic testing as part of cancer clinical trial eligibility.

Eligible Conditions

  • Lymphoma
  • Thoracic Cancers
  • Gastrointestinal Cancers

Treatment Effectiveness

Study Objectives

2 Primary · 10 Secondary · Reporting Duration: From the end of accrual, up to 3 years following study initiation

Year 3
Change in readiness and awareness of clinical trials
Clinical trial awareness/readiness and PROFILE genomic testing correlates
Consent rates to PROFILE
Consent to PROFILE genomic testing and precision clinical trial enrollment
Consent to PROFILE genomic testing but insufficient tissues for sequencing
Consent to PROFILE genomic testing but no archival tissue for sequencing
Consent to PROFILE genomic testing with GI TARGET review and precision clinical trial enrollment
Consent to Rapid Heme Panel and precision clinical trial enrollment
Initial readiness and awareness of clinical trials
No consent to PROFILE genomic testing after video
PROFILE genomic testing completion rates
Questionnaire response rate

Trial Safety

Trial Design

2 Treatment Groups

Standard of Care (SOC)
1 of 2
SURGE
1 of 2
Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: SURGE · No Placebo Group · N/A

Standard of Care (SOC)
Behavioral
Experimental Group · 1 Intervention: Standard of Care · Intervention Types: Behavioral
SURGE
Behavioral
Experimental Group · 1 Intervention: SURGE · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Standard of Care
2017
Completed Phase 4
~9880

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from the end of accrual, up to 3 years following study initiation
Closest Location: Dana Farber Cancer Institute · Boston, MA
Photo of dana farber cancer institute  1Photo of dana farber cancer institute  2Photo of dana farber cancer institute  3
2004First Recorded Clinical Trial
101 TrialsResearching Lymphoma
539 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The DFCI satellite is located at St

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.